ImmunityBio

ImmunityBio (IBRX) is about to enter a $230 billion market, the market cap is only around $2 billion at the moment. Also positive news and strong data for their enrolment for the pivotal bladder cancer study – interim analysis also indicates ‘meaningful improvements in response rates when ANKTIVA is combined with BCG’.

The FDA confirmed a clear resubmission path for ImmunityBio’s ANKTIVA plus BCG and did not request any new clinical trials. The agency asked for additional data only, which shortens timelines and strengthens confidence in expanded approval for bladder cancer studies from ImmunityBio. This is very bullish.

BEARISH factor is that an insider filed to sell shares (also yesterday – this could be profit taking or something else). Generally, the company still looks bullish.

Entered the stock and alerted this trade to our premium members.